NEW YORK, Dec. 20, 2017 /PRNewswire/ --
In keeping with the commitment to dynamically provide members with timely information, WallStEquities.com has issued free tailored Stock Review on ADMS, NEOS, MNTA, and PCRX which is a click away at www.wallstequities.com/registration. For this morning, WallStEquities.com revisits the Generic Drugs space, which can be segmented into biosimilars, simple generic, and super generic. Lined up for evaluation today are: Adamas Pharmaceuticals Inc. (NASDAQ: ADMS), Neos Therapeutics Inc. (NASDAQ: NEOS), Momenta Pharmaceuticals Inc. (NASDAQ: MNTA), and Pacira Pharmaceuticals Inc. (NASDAQ: PCRX). Free Downloads on Wall St. Equities today, sign up now and access these stocks' research reports at: www.wallstequities.com/registration
Emeryville, California headquartered Adamas Pharmaceuticals Inc.'s stock finished Tuesday's session 0.54% higher at $31.90 with a total trading volume of 813,942 shares. Over the last month and the previous three months, the Company's shares have advanced 12.28% and 49.27%, respectively. Additionally, the stock has surged 88.76% since the start of this year. Shares of the Company are trading above their 50-day and 200-day moving averages by 15.85% and 58.87%, respectively. Moreover, shares of Adamas Pharma, which discovers, develops, and sells chrono-synchronous therapies for chronic neurologic disorders, have a Relative Strength Index (RSI) of 51.93.
On November 29th, 2017, research firm Northland Capital initiated an 'Outperform' rating on the Company's stock, with a target price of $70 per share.
On December 08th, 2017, Adamas Pharma announced that the compensation committee of its board of directors granted 64 new employees the option to purchase an aggregate of 77,550 shares of the Company's common stock, at a per share exercise price of $35.76, the closing trading price on December 07th, 2017, and restricted stock units to acquire 38,775 shares of the Company's common stock. Free Access to this morning's research report on ADMS at: www.wallstequities.com/registration/?symbol=ADMS
Shares in Grand Prairie, Texas headquartered Neos Therapeutics Inc. declined 0.52%, ending yesterday's session at $9.65 with a total trading volume of 249,967 shares. The stock has gained 10.92% in the previous three months and 64.96% on an YTD basis. The Company's shares are trading 0.57% above their 50-day moving average and 19.48% above their 200-day moving average. Moreover, shares of Neos Therapeutics, which engages in the development, manufacture, and commercialization of products for the treatment of attention deficit hyperactivity disorder using its drug delivery technologies, has an RSI of 50.68. Find your free research report NEOS at: www.wallstequities.com/registration/?symbol=NEOS
On Tuesday, Cambridge, Massachusetts headquartered Momenta Pharmaceuticals Inc.'s stock saw a correction of 1.89%, to close the day at $13.00. A total volume of 478,843 shares was traded. The Company's shares are trading 2.56% below their 50-day moving average. Additionally, shares of Momenta Pharma, which focuses on developing generic versions of complex drugs, biosimilars, and novel therapeutics for autoimmune diseases in the US, have an RSI of 47.38. Sign up today for the free research report on MNTA at: www.wallstequities.com/registration/?symbol=MNTA
Shares in Parsippany, New Jersey headquartered Pacira Pharmaceuticals Inc. ended the day 2.12% lower at $41.65. A total volume of 749,190 shares was traded. The stock has gained 3.48% in the last one month, 16.02% in the previous three months, and 28.95% since the start of this year. The Company's shares are trading above their 50-day moving average by 6.36%. Furthermore, shares of Pacira Pharma, which develops, manufactures, and commercializes proprietary pharmaceutical products primarily for use in hospitals and ambulatory surgery centers in the US, have an RSI of 46.77.
On December 07th, 2017, Pacira Pharma announced that Scott Braunstein, MD has been named COO, and Richard Scranton, MD has been named Chief Scientific Officer. In this new role, Dr. Braunstein will oversee the Company's commercial and medical affairs functions while continuing to manage strategy and corporate development. As Chief Scientific Officer, Dr. Scranton will direct the Company's clinical research while continuing to lead scientific communications, market access, and health outcomes research and analytics for EXPAREL® (bupivacaine liposome injectable suspension).
On December 18th, 2017, research firm JP Morgan initiated a 'Neutral' rating on the Company's stock, with a target price of $47 per share. Wall St. Equities' research coverage also includes the downloadable free report on PCRX at: www.wallstequities.com/registration/?symbol=PCRX
Wall St. Equities:
Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
WSE has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email email@example.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit https://wallstequities.com/legal-disclaimer/
For any questions, inquiries, or comments reach out to us directly. If you're a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Phone number: +21-32-044-483
Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Wall St. Equities